NASDAQ:DUSA - DAVIS FUNDAMENT/SELECT US EQUITY ET Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.59 +0.18 (+0.74 %)
(As of 06/20/2018 01:04 PM ET)
Previous Close$24.4150
Today's Range$24.45 - $24.6190
52-Week Range$20.72 - $25.32
Volume3,347 shs
Average Volume9,611 shs
Market Capitalization$108.55 million
P/E RatioN/A
Dividend Yield0.65%
BetaN/A
DUSA Pharmaceuticals, Inc. (DUSA) is a vertically integrated dermatology company. The Company is developing and marketing Levulan photodynamic therapy (Levulan PDT). The Company's marketed products include Levulan Kerastick 20% topical solution with PDT and the BLU-U brand light source. Levulan Kerastick and BLU-U are used for the treatment of non-hyperkeratotic actinic keratoses (AKs), of the face or scalp. During the year ended December 31, 2011, it initiated an exploratory DUSA-sponsored clinical trial designed to study the broad area application and/or short drug incubation (BASDI), method of using the Levulan Kerastick, which is being carried out at 10 clinical trial sites. DUSA manufactures its Levulan Kerastick in its Wilmington, Massachusetts facility. Its wholly owned subsidiaries include DUSA Pharmaceuticals New York, Inc. and Sirius Laboratories, Inc. As of December 31, 2011, DUSA ceased marketing and selling its remaining Non-PDT products, which were ClindaReach and Meted.

Receive DUSA News and Ratings via Email

Sign-up to receive the latest news and ratings for DUSA and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Davis Advisors
Fund NameDavis Select U.S. Equity ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:DUSA
Inception Date1/11/2017
Fund ManagerChristopher Davis, Danton Goei
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNot Applicable
CategorySize and Style
FocusLarge Cap
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$108.21 million
Average Daily Volume$5,026.00
Discount/Premium0.34%

ETF Expenses

Management Fee0.55%
Other Expenses0.26%
Total Expenses0.81%
Fee Waiver-0.16%
Net Expenses0.65%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorDavis Selected Advisers, L.P.
CustodianState Street Bank and Trust Company
DistributorForeside Fund Services, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of DAVIS FUNDAMENT/SELECT US EQUITY ET (NASDAQ:DUSA)
Currency Exposure of DAVIS FUNDAMENT/SELECT US EQUITY ET (NASDAQ:DUSA)
Sector Exposure of DAVIS FUNDAMENT/SELECT US EQUITY ET (NASDAQ:DUSA)
Industry Exposure of DAVIS FUNDAMENT/SELECT US EQUITY ET (NASDAQ:DUSA)

DAVIS FUNDAMENT/SELECT US EQUITY ET (NASDAQ:DUSA) Frequently Asked Questions

What is DAVIS FUNDAMENT/SELECT US EQUITY ET's stock symbol?

DAVIS FUNDAMENT/SELECT US EQUITY ET trades on the NASDAQ under the ticker symbol "DUSA."

How often does DAVIS FUNDAMENT/SELECT US EQUITY ET pay dividends? What is the dividend yield for DAVIS FUNDAMENT/SELECT US EQUITY ET?

DAVIS FUNDAMENT/SELECT US EQUITY ET declared a special dividend on Tuesday, December 26th. Shareholders of record on Wednesday, December 27th will be given a dividend of $0.0752 per share on Thursday, December 28th. The ex-dividend date of this dividend is Tuesday, December 26th. View DAVIS FUNDAMENT/SELECT US EQUITY ET's Dividend History.

Has DAVIS FUNDAMENT/SELECT US EQUITY ET been receiving favorable news coverage?

Media stories about DUSA stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DAVIS FUNDAMENT/SELECT US EQUITY ET earned a media sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the healthcare company an impact score of 46.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are DAVIS FUNDAMENT/SELECT US EQUITY ET's major shareholders?

DAVIS FUNDAMENT/SELECT US EQUITY ET's stock is owned by many different of retail and institutional investors. Top institutional shareholders include D.A. Davidson & CO. (0.88%), LPL Financial LLC (0.81%) and Stratos Wealth Partners LTD. (0.37%). View Institutional Ownership Trends for DAVIS FUNDAMENT/SELECT US EQUITY ET.

Which institutional investors are buying DAVIS FUNDAMENT/SELECT US EQUITY ET stock?

DUSA stock was purchased by a variety of institutional investors in the last quarter, including D.A. Davidson & CO., LPL Financial LLC and Stratos Wealth Partners LTD.. View Insider Buying and Selling for DAVIS FUNDAMENT/SELECT US EQUITY ET.

How do I buy shares of DAVIS FUNDAMENT/SELECT US EQUITY ET?

Shares of DUSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DAVIS FUNDAMENT/SELECT US EQUITY ET's stock price today?

One share of DUSA stock can currently be purchased for approximately $24.59.

How big of a company is DAVIS FUNDAMENT/SELECT US EQUITY ET?

DAVIS FUNDAMENT/SELECT US EQUITY ET has a market capitalization of $108.55 million.


MarketBeat Community Rating for DAVIS FUNDAMENT/SELECT US EQUITY ET (DUSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about DAVIS FUNDAMENT/SELECT US EQUITY ET and other stocks. Vote "Outperform" if you believe DUSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DUSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.